What is AxoGen, Inc. (AXGN)?

AxoGen, Inc. (AXGN) is a stock in the Healthcare sector, Medical - Devices industry. View full analysis on Stocks360.

What is the current price of AXGN?

The current price of AXGN is $49.25. Prices are updated in real time on Stocks360.

What is AXGN's price-to-earnings (PE) ratio?

AXGN's trailing twelve-month PE ratio is -75.77, based on current price and earnings per share data available on Stocks360.

What is AXGN's market capitalization?

AXGN's market capitalization is $2,889,571,375.00, placing it in the mid-cap tier.

AxoGen, Inc. (AXGN)

Stock analysis · NASDAQ · Healthcare · Medical - Devices

$49.25

Market Cap

$2.89B

PE (TTM)

-75.77

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.17

Day Range

$43.50 – $49.97

52-wk Range

$18.46 – $52.91

Avg Volume

N/A

Volume

9.28M

AxoGen, Inc. (AXGN) is a publicly traded company in the Healthcare sector. Latest price: $49.25. Market cap $2.89B. Trailing PE -75.77. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 4 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-29 · $22.25 2026-10-28 · $49.25 (+121.35%)

Earnings

Most Recent

Oct 28, 2026

EPS $0.21 vs est. $0.13

Beat by $0.08

Next Earnings

Feb 23, 2027

EPS estimate $0.14

Proprietary Signals

Signal snapshot temporarily unavailable.

About AxoGen, Inc.

AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-75.77×
P/S (TTM)	10.83×
P/B	5.48×
PEG	0.43×
P/FCF (TTM)	177.14×
EV / EBITDA	-121.48×
EV / Sales	9.67×
Earnings Yield	-1.18%
Free Cash Flow Yield	0.56%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$2.58B
Revenue (TTM)	$266.93M
Net Income (TTM)	-$33.96M
Free Cash Flow (TTM)	$18.73M
Net Debt	-$309.42M
Working Capital	$401.64M
Gross Margin	74.18%
Operating Margin	-5.17%
Net Margin	-11.96%
Return on Equity	-11.34%
Return on Invested Capital	-2.68%